Andros Pharmaceuticals Co (ROCO:6917) Total Stockholders Equity : NT$394.17 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Total Stockholders Equity?

Andros Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was NT$394.17 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Andros Pharmaceuticals Co's Book Value per Share for the quarter that ended in Dec. 2024 was NT$8.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Andros Pharmaceuticals Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.06.

Andros Pharmaceuticals Co Total Stockholders Equity Historical Data

The historical data trend for Andros Pharmaceuticals Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Total Stockholders Equity Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

90.36

68.66

279.48

471.11

394.17

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial					279.48	255.07	471.11	438.12	394.17

Andros Pharmaceuticals Co (ROCO:6917) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Andros Pharmaceuticals Co's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(394.173	-	0)	/	44.690
	=	8.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Andros Pharmaceuticals Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.172	+	16.857)	/	394.173
	=	0.06

Andros Pharmaceuticals Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines